In the following video, Motley Fool health-care analyst David Williamson takes a continuing look at the best-performing stocks in health care for this past January. In this video, he highlights MAP Pharmaceuticals (NASDAQ: MAPP), up 58% last month because of a buyout coming from its marketing partner, Allergan (NYSE: AGN). In the video, David tells us why MAP's key product, an inhaled migraine medication called Levadex, could be an excellent synergistic win for Allergan even though the FDA rejected the drug last March, and why Allergan is much more than the company known for Botox.
Feb 5, 2013 at 4:51PM
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings... Follow @motleydavid
Motley Fool Returns
Stock Advisor S&P 500
Stock Advisor launched in February of 2002. Returns as of 02/19/2020.Join Stock Advisor
Cumulative Growth of a $10,000 Investment in Stock Advisor Calculated by Time-Weighted Return